why does nobody talk about 503A
why does nobody talk about 503A. I would rather ask a basic question now than get this wrong quietly for two months.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.
Careful. Naming a clinic without describing what actually happened turns this into a different kind of thread.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
ask which facility, then ask for their testing
the price difference is mostly the intake, not the vial
Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.
What concentration is on the label, and does it match what you were expecting?
a 503B has to register and report, so there is a paper trail to ask for
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
Removed the staff name. Facilities and clinics can be named here; individuals cannot.
ask what the beyond-use date is based on
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
the shortage list is the whole legal hinge and people skip it
the shortage list is the whole legal hinge and people skip it
Agreed — and the follow-up question is what the beyond-use date is based on.
if a clinic will not name the facility, that is your answer
salt forms are the recurring argument and the answer is boring
What is the beyond-use date and what is it based on?
potency testing on the finished preparation is the thing to ask for
the pharmacy and the prescriber are two separate questions
the API source is the question nobody asks and everybody should
Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
Asked for the beyond-use date basis and got a real answer with a stability reference attached.
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
- 1Removed the staff name. Facilities and clinics can be named here;…13 comments in this branch · started by u/quiet_moderator
- 2Nothing in this thread is medical advice, and the choice between…7 comments in this branch · started by u/eu_apotheke_a